clinical trial · NCT06782542
Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy
Justin Watts, MD·phase2·recruiting·n = 16
Acute Myeloid LeukemiaIDH1 MutationOlutasidenibVenetoclaxAzacitidine
brief summary
The purpose of this study is as follows: 1. Determine whether people receiving the combination treatment of olutasidenib, venetoclax, and azacitidine have the same, more, or fewer side effects compared to the usual chemotherapy treatment that people with this condition receive. 2. Determine how well the combination treatment of olutasidenib, venetoclax, and azacitidine works compared to the usual chemotherapy treatment that people with this condition receive.
started
Mar 31, 2026
primary completion
Mar 31, 2029
completion
Mar 31, 2029
last updated
Apr 16, 2026
official title
Single-Arm Phase 2 Study of Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Who Are Eligible for Intensive Induction Chemotherapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol